Stockscreener 앱 받기
5.59
1.82%
0.10
시간 외 거래:
5.59
전일 마감가:
$5.49
열려 있는:
$5.57
하루 거래량:
2.72M
Relative Volume:
1.00
시가총액:
$1.61B
수익:
$9.77M
순이익/손실:
$-109.00M
주가수익비율:
-15.51
EPS:
-0.3604
순현금흐름:
$-93.83M
1주 성능:
+7.81%
1개월 성능:
-12.66%
6개월 성능:
+15.02%
1년 성능:
+103.27%
1일 변동 폭
$5.445
$5.695
1주일 범위
$5.17
$5.695
52주 변동 폭
$2.25
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.59 | 1.58B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance
Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 77% Upside in the Biotech Sector - DirectorsTalk Interviews
Taysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysis - MSN
Taysha (TSHA) Advances Clinical Development Strategy for TSHA-10 - GuruFocus
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Taysha Gene Therapies Q1 2026 earnings preview - MSN
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies Q1 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies Q1 2026 Earnings Call Transcript - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
TSHA: Pivotal trial dosing and regulatory milestones for TSHA-102 on track amid strong market demand - TradingView
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Nigeria
Taysha Gene Therapies: Runway to Fund Planned Operating Expenses Into 2028 >TSHA - Moomoo
TSHA: Pivotal trial dosing on track, strong efficacy and safety, and cash runway into 2028 - TradingView
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Taysha Gene Therapies | 10-Q: Q1 2026 Earnings Report - Moomoo
Taysha Gene Therapies Reports Q1 2026 Results, Advances TSHA-102 Pivotal Trials and FDA BLA Submission for Rett Syndrome Therapy - Minichart
Rising R&D spend widens Taysha Gene Therapies (NASDAQ: TSHA) Q1 loss - Stock Titan
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TSHA: Q1 2026 net loss widened to $42.4M as TSHA-102 pivotal trials advanced toward BLA submission - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway - Stock Titan
Taysha Gene Therapies Q1 net loss widens on higher R&D costs - TradingView
A 6-month trial readout could shape Taysha's gene therapy filing - Stock Titan
BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million - TradingView
Taysha Gene Therapies stock hits 52-week high at 6.77 USD - Investing.com Australia
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com - Investing.com South Africa
Taysha Gene earnings loom with pivotal trial data on horizon - Investing.com
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Taysha Gene Therapies Inc 주식 (TSHA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
0.98%
0.12%
자본화:
|
볼륨(24시간):